Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Giant leap for MannKind's Affrezza as Colby takes immunotherapies off back burner

This article was originally published in Scrip

Executive Summary

MannKind stands to gain up to $140 million in upfront and milestone payments plus royalties under a license agreement with Colby Pharmaceutical, which will take over development of novel MKC1106 immunotherapies, allowing MannKind to move another oncology asset forward while remaining focused on Phase III development of its inhaled diabetes drug Affrezza.

You may also be interested in...



Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements

Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.

Janux Soars On Early Efficacy, Safety For ‘Masked’ T-Cell Engagers

Janux reported early clinical trial data for its lead asset JANX007 that may show differentiated efficacy in the crowded PSMA space and for an EGFR agent with lung and kidney tumor shrinkage.

Incyte Enters A Data-Rich Year On Path To Portfolio Diversification

Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC019434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel